Mather Group’s GSK GSK Stock Holding History

Mather Group’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$212K	Buy	4,405 +1,890	+75%	+$96.5K	﹤0.01%	779
2026 Q2	$132K	Buy	2,515 +1,241	+97%	+$65.6K	﹤0.01%	870
2026 Q1	$70.3K	Buy	+1,274	New	+$69K	﹤0.01%	977
2025 Q4	–	Sell	-755	Closed	-$32.6K	–	1053
2025 Q3	$32.6K	Buy	+755	New	+$29.5K	﹤0.01%	1007
2025 Q2	–	Sell	-425	Closed	-$16.5K	–	1062
2025 Q1	$16.5K	Buy	425 +133	+46%	+$4.87K	﹤0.01%	1134
2024 Q4	$9.9K	Sell	292 -436	-60%	-$15.7K	﹤0.01%	1251
2024 Q3	$29.7K	Buy	728 +185	+34%	+$7.57K	﹤0.01%	978
2024 Q2	$23.3K	Buy	543 +305	+128%	+$12.8K	﹤0.01%	1233
2024 Q1	$8.82K	Buy	+238	New	+$9.8K	﹤0.01%	1231

Other funds holding GSK

Mondrian Investment Partners London, United Kingdom $5.39B AUM 14.53% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $13.1B AUM 35.37% 1-Year Est. Return

Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

ABC Arbitrage Paris, France $1.02B AUM 30.46% 1-Year Est. Return

Foster Victor Wealth Advisors Greenville, South Carolina $2.02B AUM 20.94% 1-Year Est. Return

Sound Income Strategies Ft Lauderdale, Florida $2.24B AUM 8.38% 1-Year Est. Return

Euro Pacific Asset Management Dorado, Puerto Rico $1.22B AUM 22.48% 1-Year Est. Return

Keystone Financial Planning Cleveland, Ohio $404M AUM 16.77% 1-Year Est. Return

Bell Bank Fargo, North Dakota $2.66B AUM 18.07% 1-Year Est. Return

Mather Group's GSK Position: Q3 2026 in Review

Mather Group increased its GSK (GSK) stake by 75% in Q3 2026, buying an estimated $96.5K and bringing the position to 4,405 shares worth $212K. The position accounts for ﹤0.01% of the portfolio, ranked #779.

Mather Group first reported a position in GSK in Q1 2024 and has held it in 9 quarters since. 253 funds tracked by Wall St. Rank hold GSK as of Q3 2026.

Mather Group held 4,405 shares of GSK worth $212K as of Q3 2026.
Mather Group bought 1,890 GSK shares in Q3 2026, an estimated $96.5K.
GSK made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #779 holding.
Mather Group first reported a position in GSK in Q1 2024 and has held it in 9 quarters since.
253 funds tracked by Wall St. Rank held GSK as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.